Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortages

Novo Nordisk is investing $6 billion to address shortages and high demand for its weight loss drugs, Ozempic and Wegovy. Despite this investment, delays in market availability are expected. The company has also acquired three production facilities to boost production capacity. Additionally, Novo Nordisk is working with insurers and lawmakers to reduce costs and expand coverage for these medications.